Bannerbild German Brest Group - Forschung

Paper des Monats

  • 01.02.2019 February 2019: Results of the GeparOcto trial

    We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.

  • 17.12.2018 Results of an interim analysis from KATHERINE trial

    We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.

  • 30.11.2018 November 2018: Exploratory analysis on obese breast cancer patients from the PANTHER trial

    Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment have been published in the Annals of Oncology.

  • 05.11.2018 October 2018: Long-term survival analysis of GeparSixto trial

    The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.

  • 27.09.2018 Paper of the month: models for pCR

    Paper of the month: models for pCR

    A statistical research study that aimed to develop an empirical model for predicting the magnitude of the treatment effects on survival endpoints based on the treatment effects on pathological complete response (pCR) has been published in the Contemporary Clinical Trials.

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd